Evidence map›Paper›PMID 33361777›Full record

ArticleScientific reports2020

Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.

Brandon Malone, Boris Simovski, Clément Moliné, Jun Cheng, Marius Gheorghe, Hugues Fontenelle, Ioannis Vardaxis, Simen Tennøe, Jenny-Ann Malmberg, Richard Stratford and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Temperature imaging inside fluid devices using a ratiometric near infrared (NIR-II/III) fluorescent YAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. Digital Twins in Healthcare and Their Applicability in Rhinology: A Narrative Review.Journal of rhinology : official journal of the Korean Rhinologic Society · 2023
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Robust spike-specific CD4Frontiers in immunology · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Brandon MaloneNEC Laboratories Europe GmbH, Kurfuersten-Anlage 36, 69115, Heidelberg, Germany.
Boris SimovskiNEC OncoImmunity AS, Ullernchausseen 64/66, 0379, Oslo, Norway.
Clément MolinéNEC OncoImmunity AS, Ullernchausseen 64/66, 0379, Oslo, Norway.
Jun ChengNEC Laboratories Europe GmbH, Kurfuersten-Anlage 36, 69115, Heidelberg, Germany.
Marius GheorgheNEC OncoImmunity AS, Ullernchausseen 64/66, 0379, Oslo, Norway.
Hugues FontenelleNEC OncoImmunity AS, Ullernchausseen 64/66, 0379, Oslo, Norway.
Ioannis VardaxisNEC OncoImmunity AS, Ullernchausseen 64/66, 0379, Oslo, Norway.
Simen TennøeNEC OncoImmunity AS, Ullernchausseen 64/66, 0379, Oslo, Norway.
Jenny-Ann MalmbergNEC OncoImmunity AS, Ullernchausseen 64/66, 0379, Oslo, Norway.
Richard StratfordNEC OncoImmunity AS, Ullernchausseen 64/66, 0379, Oslo, Norway.
Trevor ClancyNEC OncoImmunity AS, Ullernchausseen 64/66, 0379, Oslo, Norway. trevor@oncoimmunity.com.
OncoImmune (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global population is at present suffering from a pandemic of Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The goal of this study was to use artificial intelligence (AI) to predict blueprints for designing universal vaccines against SARS-CoV-2, that contain a sufficiently broad repertoire of T-cell epitopes capable of providing coverage and protection across the global population. To help achieve these aims, we profiled the entire SARS-CoV-2 proteome across the most frequent 100 HLA-A, HLA-B and HLA-DR alleles in the human population, using host-infected cell surface antigen presentation and immunogenicity predictors from the NEC Immune Profiler suite of tools, and generated comprehensive epitope maps. We then used these epitope maps as input for a Monte Carlo simulation designed to identify statistically significant "epitope hotspot" regions in the virus that are most likely to be immunogenic across a broad spectrum of HLA types. We then removed epitope hotspots that shared significant homology with proteins in the human proteome to reduce the chance of inducing off-target autoimmune responses. We also analyzed the antigen presentation and immunogenic landscape of all the nonsynonymous mutations across 3,400 different sequences of the virus, to identify a trend whereby SARS-COV-2 mutations are predicted to have reduced potential to be presented by host-infected cells, and consequently detected by the host immune system. A sequence conservation analysis then removed epitope hotspots that occurred in less-conserved regions of the viral proteome. Finally, we used a database of the HLA haplotypes of approximately 22,000 individuals to develop a "digital twin" type simulation to model how effective different combinations of hotspots would work in a diverse human population; the approach identified an optimal constellation of epitope hotspots that could provide maximum coverage in the global population. By combining the antigen presentation to the infected-host cell surface and immunogenicity predictions of the NEC Immune Profiler with a robust Monte Carlo and digital twin simulation, we have profiled the entire SARS-CoV-2 proteome and identified a subset of epitope hotspots that could be harnessed in a vaccine formulation to provide a broad coverage across the global population.

Indexed as

Machine LearningProteomeAlgorithmsAllelesAmino Acid SequenceCOVID-19COVID-19 VaccinesDrug Evaluation, PreclinicalEpitopes, T-LymphocyteHaplotypesHLA AntigensHumansImmunogenicity, VaccineMutationPandemicsProteomicsCOVID-19 VaccinesEpitopes, T-LymphocyteHLA AntigensProteomeSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID33361777
PMCPMC7758335
OpenAlexW3114324465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.